Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | GeneticVariation | BEFREE | Calreticulin (CALR) gene mutations are currently recommended as biomarkers in diagnosis of patients with myeloproliferative neoplasms (MPN) with Jak2 V617F negative phenotype. | 31248375 | 2019 |
||||
|
0.070 | GeneticVariation | BEFREE | Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera and primary myelofibrosis are associated with JAK2 (V617F) mutations. | 24475114 | 2014 |
||||
|
0.070 | GeneticVariation | BEFREE | The JAK2-V617F mutation is prevalent in almost all patients with MPNs and has become a valuable biomarker for diagnosis of MPNs. | 24362471 | 2014 |
||||
|
0.070 | GeneticVariation | BEFREE | JAK2 V617F mutation is a molecular marker for myeloproliferative neoplasms (MPNs). | 25015634 | 2014 |
||||
|
0.070 | GeneticVariation | BEFREE | The Janus kinase 2 (JAK2) V617F mutation has considerably helped understanding of the molecular pathogenesis of chronic myeloproliferative disorders (MPD), hence this study investigated for the first time the mutational status and relative quantitation of JAK2 V617F mRNA in Chinese patients with chronic MPD. | 19215672 | 2009 |
||||
|
0.070 | GeneticVariation | BEFREE | Presence of JAK2(V617F) in bone marrow might therefore increase the risk of future MPD development, just as monoclonal gammopathy of undetermined significance (MGUS) increases the risk of multiple myeloma. | 18032883 | 2007 |
||||
|
0.070 | GeneticVariation | BEFREE | We propose that this method might complement current technologies based on genomic DNA analysis, and lead prospectively to a better clinically oriented assessment of the impact of JAK2(V617F) mutation in MPD. | 16572198 | 2006 |